Buruli Ulcer Disease: Cuting off the surgery
T.E. Hoornweg, s1619578 ; Supervisor: T.S. new wave der Werf
Buruli Ulcer Disease ( BUD ) is one of the 14 neglected tropical diseases assigned by the World Health Organization ( WHO ) 1. Although the first study of BUD dates back to 1897, the first unequivocal description is from The Democratic Republic of Congo in 19481. However, in recent old ages many states of sub-Saharan Africa are endemic for BUD and an alarming addition in figure of detected instances has been reported from distinguishable parts of Benin, C & A ; ocirc ; te d’Ivoire and Ghana. There the disease imposes a big load on affected populations, taking to societal stigmatisation and loss of livelihood1-3.
The disease is chiefly found in riverine countries with a humid hot, clime. It has been observed scattered around the universe, with focal point in Africa, Asia and South America. However, BUD has besides been found to happen in temperate climes in Australia. Up to now mode of transmittal is still non wholly elucidated, although perforating skin injury in and around H2O is thought to inoculate Mycobacterium ulcerans – the disease doing pathogen – into hypodermic tissues 2,4-6.
Buruli Ulcer is chiefly observed in kids, impacting the hypodermic fat tissue4. Clinical image ranges from painless nodules to big undetermined lesions that heal spontaneously but easy. The disease does non hold many systemic effects, likely because of production of Mycolactone – a diffusible cytotoxin with immunomodulary properties7,8 – by M. ulcerans5,6. Still, extended scarring of lesions can take to contracture of the limbs, sightlessness, malformations and other inauspicious results. 1,2,4-6
Since 1948, many different therapies have been explored, but until late extended debridement surgery was still the standard therapy for disease1. Although early deletion of non-ulcerated papules and nodules is healing, surgical direction of advanced disease is difficult5. Unfortunately, many patients present late since they live in rural countries and households can non afford clip to go to infirmaries or because patients foremost attend a ritual therapist as they believe witchery and expletives are the cause of disease9. Furthermore, many patients fear surgery, as many patients suffer from functional damages after surgery, or do non hold entree to surgical treatment1,4,6,9,10.
Sometimes, for case in patients witch facial lesions surgery is non even an option. And yet, as surgical intervention does non merely have a hapless acceptableness and high costs, it besides can non wholly take all bacteriums and returns of disease are common1. Therefore, there is a great demand for other interventions than surgical debridement.
Other interventions, like antimycobacterial agents, are active against M. ulcerans in vitro, and are bacteriocidal in carnal models1,4. However, these consequences were non met in clinical feelings. Merely really few randomized controlled tests were done and those bing are excessively little or inconclusive11,12. Therefore, possible good effects could be overlooked because good agent regimens were ne’er decently tested or because effects are non straight seeable because of irreversible tissue harm and necrosis6,13.
Based on pilot surveies and some experimental surveies the WHO recommended a combination of rifampicin an streptomycin for 8 hebdomads for pull offing BUD, trusting to cut down surgery and lessening backsliding. A little clinical test showed a lower limit of 4 hebdomads intervention with this combination inhibits growing of M. ulcerans in nodules and plaques13,14. However, the size of the test was excessively little to be conclusive and efficiency in forestalling backsliding was non evaluated.
Therefore, Nienhuis et al. put up a big randomized control test look intoing whether antimycobacterial intervention was able to bring around BUD and whether a switch to unwritten intervention, which is preferred over injection of antimicrobic therapeutics in endemic African, would give comparable results1.
In their survey Nienhuis et Al. indiscriminately assigned patients with early, limited, confirmed M. ulcerans infection into two research groups. In one group patients received 8 hebdomads of intervention with rifampicin and streptomycin, in the other group patients received 4 hebdomads intervention with rifampicin and streptomycin followed by an unwritten combination of clarithromycin and rifampicin for 4 hebdomads. Treatment was straight observed at the nearest wellness installation and patients were followed up to one twelvemonth after the start of intervention. Primary end point of their survey was recurrence-free healing at one twelvemonth after start of intervention without extended surgical debridement.
151 patients enrolled in the survey were divided in a group of 76 patients having 8 hebdomads of intramuscular injections of rifampicin and streptomycin and 75 patients having 4 hebdomads rifampicin and streptomycin injections, followed by 4 hebdomads unwritten intervention of rifampicin and clarithromycin. Overall mending rate was 93 % and no important difference in primary end point was found between both groups. Besides no return of disease was observed and few but similar rates of side effects were recorded in both groups.
Nienhuis et Al. concluded that limited BUD can be safely and efficaciously treated by antimycobacterials without debridement surgery. Furthermore exchanging to unwritten therapy after 4 hebdomads provides similar efficaciousness as 8 hebdomads of intramuscular rifampicin and streptomycin injections.
Therefore in this survey Nienhuis et Al. turn out efficaciousness of antimicrobic intervention and clear waies for less expensive and better distributable therapies against BUD, preferentially unwritten intervention. This is a major progress as the bulk of patients live in distant resource-poor, rural countries. Besides it establishes antimycobacterial intervention for people, in whom streptomycin intervention is non an option. Because antimicrobic intervention is preferred logistically, financially and ethically over debridement surgery, this determination should hold a immense clinical impact on the direction of BUD.
However, although the survey has a big proportion of patients which could be followed up to 52 hebdomads after start of intervention and about all patients were laboratory confirmed M. ulcerans instances, it should be said that the set-up of the survey was non wholly optimum. The test squad executing measurings were non blinded for intervention allotment and besides patients were cognizant of which intervention they were given. Besides there was no formal external monitoring. Partially, this could be prevented by planing the survey dual blind, dual silent person, but such a set-up would necessarily raise ethical inquiries about unneeded injection of placebo into kids put on the lining development of injection abscesses or other side effects and doing injury and emphasis on the kids.
To antagonize blinding and monitoring jobs, research workers let two independent lesion experts from the University Medical Centre Groningen, blinded for intervention group, besides assess primary study end point utilizing digital exposure. Since their consequences did non change the survey consequences significantly, hardiness of the survey is strengthened.
Though, survey design has another defect. The WHO advocated 8 hebdomads of intervention with streptomycin and rifampicin. Yet there is no grounds that 8 hebdomads is the optimum length of intervention continuance. In an earlier pilot survey no feasible Mycobacteria could be cultured after 4 hebdomads of intervention with Streptomycin and Rifampicin14. In this survey merely after four hebdomads this intramuscular intervention is switched to unwritten intervention enchantress Rifampicin and Clarithromycin. There could be a opportunity that at the clip this switch was made no or really few feasible Mycobacterias were left and unwritten intervention does non hold any extra good consequence in M. ulcerans intervention. Therefore, I feel it can non be said that unwritten intervention works every bit good as the injection intervention. Another interesting fact, back uping my ideas, is that all 5 patients in which feasible M. ulcerans was found after intervention, belonged to the group switched to unwritten intervention after 4 hebdomads. Interestingly, merely 2 of the 5 patients belonged to the group that failed intervention, so the deduction of these findings are non wholly clear.
There are still a batch of inquiries on this subject that needs to be elucidated. For case, it would be interesting to look into why feasible M. ulcerans could still be cultured from 3 patients in which disease did non repeat within 52 hebdomads. Besides the inquiry whether unwritten intervention entirely is sufficient for direction of BUD remains to be answered. Furthermore, the efficaciousness of antimycobacterials in more advanced BUD is non known. Another interesting inquiry, which is non addressed in this survey, is whether antimycobacterial intervention has consequence on the bar of disablements. Because many patients of BUD acquire distortions, this is a really relevant inquiry that should be addressed in the hereafter. In add-on, intervention of BUD with antimycobacterials is a clip devouring procedure, so farther probe is needed to clarify the possibility to rush up the good effects of antimycobacterials. Hence a batch of research can and should still be done in the hereafter.
Concluding, Nienhuis et Al. showed the efficiency of antimycobacterial intervention for BUD in a big control randomized survey. Furthermore, there was a low rate of return, implicating the good effects of antimycobacterial intervention over surgery. Switch overing to unwritten therapy after 4 hebdomads of streptomycin and rifampicin is shown to hold similar clinical result as 8 hebdomads of intramuscular injections of streptomycin and rifampicin. However, in my sentiment the survey does non turn out the consequence of unwritten intervention and farther surveies have to be performed. Still, this survey is a measure frontward turn outing efficiency and good effects of other therapies than surgery in BUD, which will hopefully better the intervention and direction of Buruli Ulcer Disease.
- Nienhuis W.A. et Al. Antimicrobial intervention for early and limited Mycobacterium ulcerans infection – a randomised controlled test. RCT for BUD alteration Oct 31, 2009 – 09-3057R1.
- Van der Werf T.S. et Al. Mycobacteria ulcerans disease. Bull World Health Organ. 2005 Oct ; 83 ( 10 ) :785-91.
- Stienstra Y. et Al. Factors associated with functional restrictions and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health. 2005 Dec ; 10 ( 12 ) :1251-7
- Stienstra Y. et Al. Susceptibility to development of Mycobacterium ulcerans disease: reappraisal of possible hazard factors. Trop Med Int Health. 2001 Jul ; 6 ( 7 ) :554-62.
- Van der Werf T.S. et Al. Mycobacterium ulcerans infection. Lancet. 1999 Sep 18 ; 354 ( 9183 ) :1013-8.
- Van der Werf T.S. et Al. Mycolactones and Mycobacterium ulcerans disease. Lancet. 2003 Sep 27 ; 362 ( 9389 ) : 1062-4.
- Philips R. et Al. Immunosuppressive Signature of Cutaneous Mycobacterium ulcerans Infection in the Peripheral Blood of Patients with Buruli Ulcer Disease. J Infect Dis. 2009 Dec 1 ; 200 ( 11 ) :1675-84.
- Coutanceau E. et Al. Selective suppression of dendritic cell maps by Mycobacterium ulcerans toxin mycolactone. Journal of Experimental Medicine. 2007 Jun 11 ; 204 ( 6 ) : 1395-403
- Mulder A.A. et Al. Healthcare seeking behavior for Buruli ulcer in Benin: a theoretical account to capture therapy pick of patients and healthy community members. Minutess of the Royal Society of Tropical Medicine and Hygiene ( 2008 ) 102, 912-920
- Barogui Y. et Al. Functional Limitations after Surgical or Antibiotic Treatment for Buruli Ulcer in Benin. Am. J. Trop. Med. Hyg. , 81 ( 1 ) , 2009, pp. 82-87
- Espey D.K. et Al. Pilot survey of intervention of Buruli ulcer with Rifadin and dapsone. Int J Infect Dis. 2002 Mar ; 6 ( 1 ) :60-5
- Revell W.D. et Al. A controlled test of the intervention of Mycobacterium ulcerans infection with clofazimine. Lancet 1973 Oct 20 ; 2 ( 7834 ) :873-7.
- Sizaire V. et Al. Mycobacterium ulcerans infection: control, diagnosing, and intervention. Lancet Infect Dis 2006 ; 6:288-96.
- Etuaful S. et Al. Efficacy of the combination rifampin-streptomycin in forestalling growing of Mycobacterium ulcerans in early lesions of Buruli ulcer in worlds. Antimicrob Agents Chemother 2005 ; 49 ( 8 ) :3182- 6.